血浆miR-136-5p表达水平对口腔鳞状细胞癌患者预后预测的价值

目的: 探讨血浆miR-136-5p表达水平对口腔鳞状细胞癌(OSCC)患者预后预测的价值。方法: 选择2015年1月—2018年10月儋州市人民医院收治的OSCC患者86例及正常对照组50例,采用实时荧光定量PCR技术检测2组患者血浆miR-136-5p表达水平。通过ROC曲线确定血浆miR-136-5p表达水平的最佳截断值,并以此为标准,将OSCC患者分为高miR-136-5p组(n=36)和低miR-136-5p组(n=50),对2组临床病理特征进行比较。应用Kaplan-Meier法绘制生存曲线,采用SPSS 20.0软件包中的单因素及多因素Cox回归模型,分析影响OSCC患者预后不良的危险因素。结果: OSCC组患者血浆miR-136-5p表达水平(1.27±0.51)显著低于对照组(4.38±1.26,P<0.01);血浆miR-136-5p低表达与OSCC患者的临床分期、分化程度、肿瘤直径及颈淋巴结转移有关(P<0.05)。生存分析显示,低miR-136-5p组患者总生存率(48.0%)显著低于高miR-136-5p组(68.4%,P<0.01),低miR-136-5p组患者无进展生存率(28.6%)显著低于高miR-136-5p组患者(57.8%,P<0.01)。多因素Cox回归模型分析显示,临床分期[HR(95%CI)=2.462(1.805~4.193)]、颈淋巴结转移[HR(95%CI)=2.913(2.142~5.827)]及血浆miR-136-5p表达水平<2.82[HR(95%CI)=3.856(3.114~8.205)]是影响OSCC患者预后不良的独立危险因素(P<0.05)。结论: 血浆miR-136-5p低表达与OSCC患者生存期短有关,有望作为预测OSCC预后不良的生物标志物。

Prognostic value of plasma level of miR-136-5p in patients with oral squamous cell carcinoma

PURPOSE: To investigate the prognostic value of plasma level of miR-136-5p in patients with oral squamous cell carcinoma (OSCC). METHODS: From January 2015 to October 2018, 86 OSCC patients and 50 normal controls were selected from Danzhou People's Hospital. The expression of miR-136-5p in plasma of the two groups were detected by real-time fluorescence quantitative PCR. The optimal cut-off value of plasma miR-136-5p expression level was determined by ROC curve, and OSCC patients were divided into high miR-136-5p group(n=36) and low miR-136-5p group (n=50). The clinicopathological features of the two groups were compared. Survival curves were drawn by Kaplan-Meier method. Single factor and multi factor Cox regression models in SPSS 20.0 software package were used to analyze the risk factors of poor prognosis in OSCC patients. RESULTS: The expression level of plasma miR-136-5p in OSCC group(1.27±0.51) was significantly lower than that in the control group (4.38±1.26, P<0.01). Low expression of plasma miR-136-5p was related to the clinical stage, differentiation degree, tumor diameter and cervical neck lymph node metastasis of OSCC (P<0.05). Survival analysis showed that the overall survival rate of low miR-136-5p group(48.0%) was significantly lower than that of high miR-136-5p group (68.4%,P<0.01), and the progression-free survival rate of low miR-136-5p group(28.6%) was significantly lower than that of high miR-136-5p group (57.8%,P<0.01). Multivariate Cox regression model analysis showed that clinical stage [HR(95%CI) =2.462(1.805-4.193)], cervical neck lymph node metastasis [HR (95%CI)= 2.913 (2.142-5.827)and plasma miR-136-5p expression<2.82 [HR (95%CI)=3.856 (3.114-8.205)were independent risk factors for poor prognosis of patients with OSCC(P<0.05). CONCLUSIONS: Low expression of plasma miR-136-5p is related to short survival time of OSCC patients, which is expected to be a biomarker for predicting poor prognosis of OSCC.